Best Of The IN VIVO Blog (06/2010)
This article was originally published in Start Up
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog.
You may also be interested in...
IRS guidance for the new Therapeutic Discovery Project Program limits awards to $5 million per company, but actual awards are expected to be lower due to number of applicants.
At least a dozen companies that roughly fit the description of a venture-backed, R&D focused biotech or small pharmaceutical company have gone public since mid-2009. Here we look at how valuations stack up compared to M&A and previous IPO windows.
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.